News

Hosted on MSN1mon
Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market
Celcuity's Q4 2024 earnings call highlighted significant progress in its clinical programs, particularly for gedatolisib, which is positioned as a potential new standard of care for HR-positive ...
Business Insider1mon
Celcuity Stock (CELC) Dips Despite Promising Cancer Treatment in Pipeline
Biotechnology company Celcuity’s (CELC) stock is down over 8% since it released its Q4 financial results yesterday, indicating that the company missed earnings expectations. Yet, despite recent ...
Business Insider1mon
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that ...
Yahoo Finance1mon
Celcuity Inc (CELC) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
Cash, Cash Equivalents, and Short-term Investments (End of 2024): $235.1 million. Celcuity Inc (NASDAQ:CELC) completed enrollment of the PIK3CA wild-type cohort in their VIKTORIA-1 Phase III study ...